25.3weeks
Median referral-to-treatment wait in psychiatry in the 2025 survey
Psychiatrist response rate: 1.7%; interpret cautiously.
For investors
Our goal is faster access to psychiatric assessment.
We are developing LimbusHealth Assess to reduce wait times, starting with adult ADHD. Patients prepare their history before the appointment; Limbus organizes it into a draft for doctor review. Its effect on waiting times and clinic capacity still needs to be established.
The work before the appointment
Bring the history and evidence into one draft the doctor can examine.
Our starting point is the handoff between patient preparation and doctor review. History, screening answers, and interview evidence need to become a record the doctor can question and correct. We are developing Assess around that work. The next question is how it fits the needs of adult ADHD clinics.
LimbusHealth Assess is adult ADHD assessment software being developed for patients and doctors. Before the appointment, the patient completes a guided history, screening questionnaires, and an adaptive text interview. Limbus links findings to source answers, preserves gaps and contradictions, and prepares a source-linked draft assessment report. The doctor reviews and corrects it, speaks with the patient, decides whether ADHD is the right diagnosis, and finalizes the clinical record.
The design can be examined in a fictional review example: a draft finding, evidence that needs clarification, and a doctor's correction. The example is not output from the Limbus system. It shows the responsibility we are building around: the doctor retains the decision.
First buyer · working hypothesis
Start with clinics that already assess adults for ADHD.
Our first buyer hypothesis is doctor-led clinics that already assess adults for ADHD. The proposed arrangement is clinic software access: patients provide information, doctors review the draft, and the clinic keeps responsibility for its care.
What we need to establish
We need to learn where preparing an assessment creates repeated work, who controls a clinic's software budget, and what would justify an evaluation. The initial business hypothesis is a clinic-paid software fee. Demand, price, billing method, purchasing authority, and delivery costs remain unproven.
Where larger organizations fit
Hospitals and public health systems are later buyer hypotheses. Their procurement, integration, evidence, and support requirements need separate work. They are not customers or partnerships claimed by this plan.
Background research
What the access research tells us.
These studies describe different parts of access to mental-health care. They do not measure adult-ADHD demand, the size of Limbus's market, or the effect of our software.
70%
Of psychiatrists reached could not accept an adult depression referral in a Vancouver study
Canadian Journal of Psychiatry · 2011
160 of 230 psychiatrists reached. Published in 2011; one city, not an adult-ADHD study.
2.5M
People in Canada with mental-health needs who reported inadequate care
Reported by CMHA in 2024; this includes mental-health needs beyond ADHD.
Does a source-linked draft fit the way adult ADHD clinics prepare for doctor review? That needs evidence from the people doing and purchasing the work.
We will assess that question separately from the broader access problem. The initial work is buyer discovery and fictional workflow walkthroughs. Clinical evidence and permission for patient use remain separate requirements.
Current stage
What we can show, and what we still need to establish.
Limbus reports software verification, clinical validation, regulatory review, and authorization as separate states. Progress in one does not imply completion of another.
- 01
- Intended use
- Adult ADHD assessment
- Assessment support for the first indication; not a general diagnostic engine.
- 02
- Clinical decision
- Doctor review required
- The software prepares a reviewable record. The doctor questions, corrects, and decides.
- 03
- Evidence
- Development evidence
- Software checks are engineering evidence; independent clinical validation remains open.
- 04
- Canadian pathway
- Canadian pathway unresolved
- Classification, regulatory strategy, and applicable quality-system requirements remain to be resolved.
- 05
- Patient use
- Not authorized for clinical use
- No public or clinical access is offered through this website.
The next milestone is a grounded decision about clinic fit.
The planned next step combines buyer conversations with walkthroughs using fictional cases. It should establish a recurring workflow need, the person who can buy, and the evidence a clinic would require to consider an evaluation. It should also identify where the proposed workflow creates more work or does not fit.
Clinical evidence and the Canadian regulatory pathway remain separate work requiring qualified review. These conversations and fictional walkthroughs do not establish clinical performance or authorize patient use.
The founder
Built by a psychiatrist who has practiced on the front line of the access gap.
FOUNDER RECORD
Dr. Marie Claire Bourque, MD, FRCPC, is a Royal College–certified psychiatrist practicing in British Columbia and Ontario, and the founder of Limbus Health. Her career on the front line of the access gap — emergency departments, inpatient wards, and outpatient assessment — led her to build clinician-led infrastructure that brings structure and rigor to psychiatric assessment. She is Limbus Health’s founder and sole developer, pairing clinical judgment with the engineering to deliver it.
What the deck covers.
- 01
The product and assessment workflow
What the patient provides, what Limbus prepares, and what the doctor decides.
- 02
The founder
The clinical background and product judgment behind the build.
- 03
A fictional review example
A source answer, draft finding, unresolved evidence, and a doctor’s correction. This is an illustration, not system output.
- 04
The first buyer hypothesis
Doctor-led clinics that already assess adults for ADHD, with the purchasing roles still to establish.
- 05
What is established and what needs evidence
The distinction between development work, clinical evidence, and permission for patient use.
- 06
The next milestones
The buyer, workflow, clinical, and regulatory evidence needed for the next decisions.
- 07
The initial business hypothesis
Clinic-paid software, with price, billing method, demand, and delivery costs still to test.
- 08
Development and authorization status
The unresolved Canadian pathway and the current limit on clinical use.
- 09
The next conversation and sources
The people and expertise needed next, with source notes and the limits of the commercial hypotheses and fictional example.
Access, when available, includes the PDF attachment · private backup link
Request investor access
Get the investor deck by email.
Enter the address where you want the deck. If investor access is available, Limbus will email you the PDF as an attachment and include a private backup link that remains open for 30 days. Nothing downloads on this page.
- 01
Enter your email
Use the inbox where you want to receive the deck.
- 02
Check for a Limbus Health message
When access is available, the email contains the attached PDF.
- 03
Open the deck
Open the attachment, or use the private backup link within 30 days.
NOTICE
This page and the deck are informational only. Nothing here is an offer to sell, or a solicitation of an offer to buy, securities.
Prefer email? hello@limbushealth.ai
Investor updates
Stay current between deck reviews.
Occasional notes on product progress, company milestones, evidence work, and access. A deck request never subscribes you automatically; this is a separate, explicit double opt-in.
- Focus
- Company + product
- Frequency
- Occasional
- Consent
- Double opt-in
Limbus updates
Email confirmation required
Request recorded · confirmation sent
Almost there. Check your inbox to confirm your email.
Double opt-in: your address isn’t added until you click the link we just sent. The link expires in 24 hours.
After you confirm, we’ll write only when there’s something meaningful: product milestones, company progress, and access news.